Solanezumab (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Solanezumab" in English language version.

refsWebsite

Global rank English rank

18nih.gov

4^th place

12doi.org

2^nd place

5semanticscholar.org

11^th place

8^th place

3clinicaltrials.gov

5,225^th place

4,062^nd place

2harvard.edu

18^th place

17^th place

2lilly.com

low place

1who.int

195^th place

302^nd place

1neurologylive.com

low place

1google.com

163^rd place

185^th place

1handle.net

102^nd place

76^th place

1shareholder.com

6,233^rd place

5,563^rd place

clinicaltrials.gov (Global: 5,225^th place; English: 4,062^nd place)

Clinical trial number NCT00749216 for "Solanezumab Safety Study in Japanese Patients With Alzheimer's Disease" at ClinicalTrials.gov
Clinical trial number NCT00905372 for "Effect of LY2062430 on the Progression of Alzheimer's Disease (EXPEDITION)" at ClinicalTrials.gov
Clinical trial number NCT01900665 for "Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo" at ClinicalTrials.gov

doi.org (Global: 2^nd place; English: 2^nd place)

Farlow M, Arnold SE, van Dyck CH, Aisen PS, Snider BJ, Porsteinsson AP, et al. (July 2012). "Safety and biomarker effects of solanezumab in patients with Alzheimer's disease". Alzheimer's & Dementia. 8 (4): 261–271. doi:10.1016/j.jalz.2011.09.224. PMID 22672770. S2CID 12755108.
McCartney M (July 2015). "Margaret McCartney: The "breakthrough" drug that's not been shown to help in Alzheimer's disease". BMJ. 351 h4064. doi:10.1136/bmj.h4064. PMID 26208710.
Siemers ER, Friedrich S, Dean RA, Gonzales CR, Farlow MR, Paul SM, Demattos RB (2010). "Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease". Clinical Neuropharmacology. 33 (2): 67–73. doi:10.1097/WNF.0b013e3181cb577a. PMID 20375655. S2CID 43700412.
Bates ML, Farrell ET, Eldridge MW (February 2014). "Abnormal ventilatory responses in adults born prematurely". The New England Journal of Medicine. 370 (6): 584–585. doi:10.1056/nejmx140041. PMC 4769592. PMID 24499235.
Siemers ER, Sundell KL, Carlson C, Case M, Sethuraman G, Liu-Seifert H, et al. (February 2016). "Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients". Alzheimer's & Dementia. 12 (2): 110–120. doi:10.1016/j.jalz.2015.06.1893. PMID 26238576. S2CID 19557687.
Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. (Australian Imaging Biomarkers Lifestyle (AIBL) Research Group) (April 2013). "Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study". The Lancet. Neurology. 12 (4): 357–367. doi:10.1016/S1474-4422(13)70044-9. PMID 23477989. S2CID 18181917.
Crespi GA, Hermans SJ, Parker MW, Miles LA (April 2015). "Molecular basis for mid-region amyloid-β capture by leading Alzheimer's disease immunotherapies". Scientific Reports. 5: 9649. Bibcode:2015NatSR...5.9649C. doi:10.1038/srep09649. PMC 4549621. PMID 25880481.
Watt AD, Crespi GA, Down RA, Ascher DB, Gunn A, Perez KA, et al. (2014). "Do current therapeutic anti-Aβ antibodies for Alzheimer's disease engage the target?". Acta Neuropathologica. 127 (6): 803–810. doi:10.1007/s00401-014-1290-2. hdl:11343/198431. PMID 24803227. S2CID 20139520.
DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM (July 2001). "Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease". Proceedings of the National Academy of Sciences of the United States of America. 98 (15): 8850–8855. Bibcode:2001PNAS...98.8850D. doi:10.1073/pnas.151261398. PMC 37524. PMID 11438712.
Sperling RA, Donohue MC, Raman R, Sun CK, Yaari R, Holdridge K, et al. (June 2020). "Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals". JAMA Neurology. 77 (6): 735–745. doi:10.1001/jamaneurol.2020.0387. PMC 7136861. PMID 32250387.
Insel PS, Donohue MC, Sperling R, Hansson O, Mattsson-Carlgren N (May 2020). "The A4 study: β-amyloid and cognition in 4432 cognitively unimpaired adults". Annals of Clinical and Translational Neurology. 7 (5): 776–785. doi:10.1002/acn3.51048. PMC 7261742. PMID 32315118.
Sperling RA, Donohue MC, Raman R, Rafii MS, Johnson K, Masters CL, et al. (September 2023). "Trial of Solanezumab in Preclinical Alzheimer's Disease". The New England Journal of Medicine. 389 (12): 1096–1107. doi:10.1056/NEJMoa2305032. PMC 10559996. PMID 37458272.

google.com (Global: 163^rd place; English: 185^th place)

US 7195761, "Humanized antibodies that sequester abeta peptide", issued 27 March 2007, assigned to Eli Lilly and Co. and Washington University in St Louis

handle.net (Global: 102^nd place; English: 76^th place)

hdl.handle.net

Watt AD, Crespi GA, Down RA, Ascher DB, Gunn A, Perez KA, et al. (2014). "Do current therapeutic anti-Aβ antibodies for Alzheimer's disease engage the target?". Acta Neuropathologica. 127 (6): 803–810. doi:10.1007/s00401-014-1290-2. hdl:11343/198431. PMID 24803227. S2CID 20139520.

harvard.edu (Global: 18^th place; English: 17^th place)

ui.adsabs.harvard.edu

Crespi GA, Hermans SJ, Parker MW, Miles LA (April 2015). "Molecular basis for mid-region amyloid-β capture by leading Alzheimer's disease immunotherapies". Scientific Reports. 5: 9649. Bibcode:2015NatSR...5.9649C. doi:10.1038/srep09649. PMC 4549621. PMID 25880481.
DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM (July 2001). "Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease". Proceedings of the National Academy of Sciences of the United States of America. 98 (15): 8850–8855. Bibcode:2001PNAS...98.8850D. doi:10.1073/pnas.151261398. PMC 37524. PMID 11438712.

lilly.com (Global: low place; English: low place)

lilly.com

"Lilly Integrated report 2015" (PDF). lilly.com. Eli Lilly. 2016-11-10. Retrieved 2016-11-10.

investor.lilly.com

"Lilly Announces Top-Line Results of Solanezumab Phase 3 Clinical Trial". Eli Lilly. Retrieved 23 November 2016.

neurologylive.com (Global: low place; English: low place)

Meglio M (March 10, 2023). "Solanezumab Fails Phase 3 A4 Study of Preclinical Alzheimer Disease". NeurologyLive. Retrieved August 1, 2023.

nih.gov (Global: 4^th place; English: 4^th place)

pubmed.ncbi.nlm.nih.gov

Farlow M, Arnold SE, van Dyck CH, Aisen PS, Snider BJ, Porsteinsson AP, et al. (July 2012). "Safety and biomarker effects of solanezumab in patients with Alzheimer's disease". Alzheimer's & Dementia. 8 (4): 261–271. doi:10.1016/j.jalz.2011.09.224. PMID 22672770. S2CID 12755108.
McCartney M (July 2015). "Margaret McCartney: The "breakthrough" drug that's not been shown to help in Alzheimer's disease". BMJ. 351 h4064. doi:10.1136/bmj.h4064. PMID 26208710.
Siemers ER, Friedrich S, Dean RA, Gonzales CR, Farlow MR, Paul SM, Demattos RB (2010). "Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease". Clinical Neuropharmacology. 33 (2): 67–73. doi:10.1097/WNF.0b013e3181cb577a. PMID 20375655. S2CID 43700412.
Bates ML, Farrell ET, Eldridge MW (February 2014). "Abnormal ventilatory responses in adults born prematurely". The New England Journal of Medicine. 370 (6): 584–585. doi:10.1056/nejmx140041. PMC 4769592. PMID 24499235.
Siemers ER, Sundell KL, Carlson C, Case M, Sethuraman G, Liu-Seifert H, et al. (February 2016). "Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients". Alzheimer's & Dementia. 12 (2): 110–120. doi:10.1016/j.jalz.2015.06.1893. PMID 26238576. S2CID 19557687.
Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. (Australian Imaging Biomarkers Lifestyle (AIBL) Research Group) (April 2013). "Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study". The Lancet. Neurology. 12 (4): 357–367. doi:10.1016/S1474-4422(13)70044-9. PMID 23477989. S2CID 18181917.
Crespi GA, Hermans SJ, Parker MW, Miles LA (April 2015). "Molecular basis for mid-region amyloid-β capture by leading Alzheimer's disease immunotherapies". Scientific Reports. 5: 9649. Bibcode:2015NatSR...5.9649C. doi:10.1038/srep09649. PMC 4549621. PMID 25880481.
Watt AD, Crespi GA, Down RA, Ascher DB, Gunn A, Perez KA, et al. (2014). "Do current therapeutic anti-Aβ antibodies for Alzheimer's disease engage the target?". Acta Neuropathologica. 127 (6): 803–810. doi:10.1007/s00401-014-1290-2. hdl:11343/198431. PMID 24803227. S2CID 20139520.
DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM (July 2001). "Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease". Proceedings of the National Academy of Sciences of the United States of America. 98 (15): 8850–8855. Bibcode:2001PNAS...98.8850D. doi:10.1073/pnas.151261398. PMC 37524. PMID 11438712.
Sperling RA, Donohue MC, Raman R, Sun CK, Yaari R, Holdridge K, et al. (June 2020). "Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals". JAMA Neurology. 77 (6): 735–745. doi:10.1001/jamaneurol.2020.0387. PMC 7136861. PMID 32250387.
Insel PS, Donohue MC, Sperling R, Hansson O, Mattsson-Carlgren N (May 2020). "The A4 study: β-amyloid and cognition in 4432 cognitively unimpaired adults". Annals of Clinical and Translational Neurology. 7 (5): 776–785. doi:10.1002/acn3.51048. PMC 7261742. PMID 32315118.
Sperling RA, Donohue MC, Raman R, Rafii MS, Johnson K, Masters CL, et al. (September 2023). "Trial of Solanezumab in Preclinical Alzheimer's Disease". The New England Journal of Medicine. 389 (12): 1096–1107. doi:10.1056/NEJMoa2305032. PMC 10559996. PMID 37458272.

ncbi.nlm.nih.gov

Bates ML, Farrell ET, Eldridge MW (February 2014). "Abnormal ventilatory responses in adults born prematurely". The New England Journal of Medicine. 370 (6): 584–585. doi:10.1056/nejmx140041. PMC 4769592. PMID 24499235.
Crespi GA, Hermans SJ, Parker MW, Miles LA (April 2015). "Molecular basis for mid-region amyloid-β capture by leading Alzheimer's disease immunotherapies". Scientific Reports. 5: 9649. Bibcode:2015NatSR...5.9649C. doi:10.1038/srep09649. PMC 4549621. PMID 25880481.
DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM (July 2001). "Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease". Proceedings of the National Academy of Sciences of the United States of America. 98 (15): 8850–8855. Bibcode:2001PNAS...98.8850D. doi:10.1073/pnas.151261398. PMC 37524. PMID 11438712.
Sperling RA, Donohue MC, Raman R, Sun CK, Yaari R, Holdridge K, et al. (June 2020). "Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals". JAMA Neurology. 77 (6): 735–745. doi:10.1001/jamaneurol.2020.0387. PMC 7136861. PMID 32250387.
Insel PS, Donohue MC, Sperling R, Hansson O, Mattsson-Carlgren N (May 2020). "The A4 study: β-amyloid and cognition in 4432 cognitively unimpaired adults". Annals of Clinical and Translational Neurology. 7 (5): 776–785. doi:10.1002/acn3.51048. PMC 7261742. PMID 32315118.
Sperling RA, Donohue MC, Raman R, Rafii MS, Johnson K, Masters CL, et al. (September 2023). "Trial of Solanezumab in Preclinical Alzheimer's Disease". The New England Journal of Medicine. 389 (12): 1096–1107. doi:10.1056/NEJMoa2305032. PMC 10559996. PMID 37458272.

semanticscholar.org (Global: 11^th place; English: 8^th place)

api.semanticscholar.org

Farlow M, Arnold SE, van Dyck CH, Aisen PS, Snider BJ, Porsteinsson AP, et al. (July 2012). "Safety and biomarker effects of solanezumab in patients with Alzheimer's disease". Alzheimer's & Dementia. 8 (4): 261–271. doi:10.1016/j.jalz.2011.09.224. PMID 22672770. S2CID 12755108.
Siemers ER, Friedrich S, Dean RA, Gonzales CR, Farlow MR, Paul SM, Demattos RB (2010). "Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease". Clinical Neuropharmacology. 33 (2): 67–73. doi:10.1097/WNF.0b013e3181cb577a. PMID 20375655. S2CID 43700412.
Siemers ER, Sundell KL, Carlson C, Case M, Sethuraman G, Liu-Seifert H, et al. (February 2016). "Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients". Alzheimer's & Dementia. 12 (2): 110–120. doi:10.1016/j.jalz.2015.06.1893. PMID 26238576. S2CID 19557687.
Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. (Australian Imaging Biomarkers Lifestyle (AIBL) Research Group) (April 2013). "Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study". The Lancet. Neurology. 12 (4): 357–367. doi:10.1016/S1474-4422(13)70044-9. PMID 23477989. S2CID 18181917.
Watt AD, Crespi GA, Down RA, Ascher DB, Gunn A, Perez KA, et al. (2014). "Do current therapeutic anti-Aβ antibodies for Alzheimer's disease engage the target?". Acta Neuropathologica. 127 (6): 803–810. doi:10.1007/s00401-014-1290-2. hdl:11343/198431. PMID 24803227. S2CID 20139520.

shareholder.com (Global: 6,233^rd place; English: 5,563^rd place)

files.shareholder.com

"Eli Lilly Annual Report 2015" (PDF). Eli Lilly. 2016-11-10. Retrieved 2016-11-10.

who.int (Global: 195^th place; English: 302^nd place)

International Nonproprietary Names for Pharmaceutical Substances (INN, prepublication copy), World Health Organization.

Solanezumab (English Wikipedia)

clinicaltrials.gov (Global: 5,225th place; English: 4,062nd place)

doi.org (Global: 2nd place; English: 2nd place)

google.com (Global: 163rd place; English: 185th place)

handle.net (Global: 102nd place; English: 76th place)